MPLT (MapLight Therapeutics) Research & Development: $172.25 Mil (TTM As of Mar. 2026)


MPLT MapLight Therapeutics Inc MPLT
14 GF Score
Price $37.11
! 4 Warning Signs
View Full Analysis

What is MapLight Therapeutics Research & Development?

MapLight Therapeutics MPLT +3.09% 14 Research & Development is $172.25 Mil as of Mar. 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MapLight Therapeutics's Research & Development for the three months ended in Mar. 2026 was $53.68 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $172.25 Mil.

MapLight Therapeutics  (NAS:MPLT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MapLight Therapeutics Research & Development Related Terms

MapLight Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for MapLight Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MapLight Therapeutics Research & Development Chart

MapLight Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
27.14 49.68 68.52 138.35

MapLight Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.79 26.85 27.09 64.62 53.68
MPLT
14GF Score
MapLight Therapeutics Inc MPLT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MapLight Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $172.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $172.25 Mil mean?
MapLight Therapeutics (MPLT) has a Research & Development of $172.25 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on MapLight Therapeutics and its competitors.
Is MapLight Therapeutics' Research & Development too high?
MapLight Therapeutics' current Research & Development is $172.25 Mil. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Research & Development compare to COAG and CAPR?
MapLight Therapeutics' Research & Development of $172.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MapLight Therapeutics and its competitors. MapLight Therapeutics's current Research & Development is $172.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Research & Development of $172.25 Mil. The current Research & Development is $172.25 Mil. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Research & Development is $172.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MapLight Therapeutics Business Description

Address 800 Chesapeake Drive, Redwood City, CA, USA, 94063
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score

Get the complete analysis for MPLT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.11
Price